Breeze Holdings Acquisition Corp. (BRZH, BRZHR, BRZHW) has entered into a definitive agreement to merge with YD Biopharma Limited, a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases. Upon the closing of the merger, the combined company is expected to be listed on the Nasdaq Capital Market. The merger will enable Breeze to leverage YD Biopharma's advancements in biotechnology and expand its presence in the clinical trials and cancer prevention diagnostics market.